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Summary  Atrial  ﬁbrillation  (AF)  is  the  most  frequent  heart  rhythm  disorder  in  the  general
population  and  contributes  not  only  to  a  major  deterioration  in  quality  of  life  but  also  to  an
increase in  cardiovascular  morbimortality.  The  onset  of  AF  in  the  acute  phase  of  myocardial
infarction  (MI)  is  a  major  event  that  can  jeopardize  the  prognosis  of  patients  in  the  short-,infarction;
Continuous  ECG
monitoring;
medium- and  long-term,  and  is  a  powerful  predictor  of  a  poor  prognosis  after  MI.  The  sus-
pected mechanism  underlying  the  excess  mortality  is  the  drop  in  coronary  ﬂow  linked  to  the
acceleration  and  arrhythmic  nature  of  the  left  ventricular  contractions,  which  reduce  the  left
ventricular  ejection  fraction.  The  principal  causes  of  AF-associated  death  after  MI  are  linked
to heart  failure.  Moreover,  the  excess  risk  of  death  in  these  heart  failure  patients  has  also
Abbreviations: ADMA, asymmetric NG,NG-dimethyl L-arginine; AF, atrial ﬁbrillation; CEM, continuous ECG monitoring; ECG, electro-
ardiogram; LA, left atrial/atrium; LV, left ventricular/ventricle; LVEF, left ventricular ejection fraction; MI, myocardial infarction; STEMI,
T-segment elevation myocardial infarction.
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been  associated  with  the  onset  of  sudden  death.  Whatever  its  form,  AF  has  a  major  negative
effect on  patient  prognosis.  In  recent  studies,  symptomatic  AF  was  associated  with  inhospital
mortality of  17.8%,  to  which  can  be  added  mortality  at  1  year  of  18.8%.  Surprisingly,  silent  AF
also has  a  negative  effect  on  the  prognosis,  as  it  is  associated  with  an  inhospital  mortality  rate
of 10.4%,  which  remains  high  at  5.7%  at  1  year.  Moreover,  both  forms  of  AF  are  independent
predictors  of  mortality  beyond  traditional  risk  factors.  The  frequency  and  seriousness  of  silent
AF in  the  short-  and  long-term,  which  were  until  recently  rarely  studied,  raises  the  question  of
systematically  screening  for  it  in  the  acute  phase  of  MI.  Consequently,  the  use  of  continuous
ECG monitoring  could  be  a  simple,  effective  and  inexpensive  solution  to  improve  screening  for
AF, even  though  studies  are  still  necessary  to  validate  this  strategy.  Finally,  complementary
studies also  effect  of  oxidative  stress  and  endothelial  dysfunction,  which  seem  to  play  a  major
role in  triggering  this  rhythm  disorder.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  La  ﬁbrillation  atriale  (FA)  est  le  plus  fréquent  des  troubles  du  rythme  cardiaque  dans
la population  générale  et  contribue  non  seulement  à  une  détérioration  importante  de  la  qualité
de vie  mais  aussi  à  une  augmentation  de  la  morbi-mortalité  cardiovasculaire.  L’apparition  de  la
FA dans  la  phase  aiguë  de  l’infarctus  du  myocarde  (IDM)  est  un  événement  majeur  qui  peut  met-
tre en  péril  le  pronostic  des  patients  à  court,  moyen  et  long  termes,  et  est  un  puissant  facteur
prédictif de  mauvais  pronostic  après  un  IDM.  Le  mécanisme  sous-jacent  qui  pourrait  expliquer  la
surmortalité  est  la  chute  du  débit  coronaire  lié  à  l’accélération  et  au  caractère  arythmique  des
contractions  du  ventricule  gauche,  qui  réduisent  la  fraction  d’éjection  ventriculaire  gauche.
Les principales  causes  de  décès  associées  à  la  FA  après  un  IDM  sont  liées  à  l’insufﬁsance  car-
diaque. De  plus,  le  sur-risque  de  décès  chez  ces  patients  insufﬁsants  cardiaques  est  également
associé  à  la  survenue  d’une  mort  subite  par  troubles  du  rythme  ventriculaire  graves.  Quelle  que
soit sa  forme,  la  FA  a  un  effet  négatif  important  sur  le  pronostic  du  patient.  Dans  des  études
récentes, la  FA  symptomatique  a  été  associée  à  une  mortalité  intra-hospitalière  de  17,8  %,  à
laquelle on  peut  ajouter  la  mortalité  à  1  an  de  18,8  %.  De  manière  très  intéressante,  la  FA
silencieuse  a  également  un  effet  négatif  sur  le  pronostic  des  patients  après  un  IDM,  avec  une
mortalité intra-hospitalière  de  10,4  %  et  qui  reste  élevée  à  un  an  à  5,7  %.  De  plus,  la  surv-
enue d’une  FA  quelle  que  soit  sa  forme  est  un  facteur  prédictif  indépendant  de  la  mortalité
au-delà de  facteurs  de  risque  traditionnels.  La  fréquence  de  survenue  et  l’impact  pronostic
à court  et  long  termes  des  épisodes  silencieux  de  FA,  qui  n’avaient  jusqu’à  été  que  rarement
étudiés, soulèvent  la  question  du  dépistage  systématique  de  la  Fa  silencieuse  à  la  phase  aiguë  de
l’IDM. Par  conséquent,  l’utilisation  du  monitoring  en  continu  de  l’ECG  pourrait  être  une  solution
simple, efﬁcace  et  peu  coûteuse  pour  améliorer  le  dépistage  des  épisodes  de  FA  silencieuse,
même si  des  études  sont  encore  nécessaires  pour  valider  cette  stratégie.  Enﬁn,  des  études
complémentaires  semblent  également  prouver  l’implication  du  stress  oxydatif  et  de  la  dysfonc-
tion endothéliale,  qui  semblent  jouer  un  rôle  majeur  dans  le  déclenchement  de  ce  trouble  du
rythme.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Atrial  ﬁbrillation  (AF)  is  the  most  frequent  heart  rhythm  dis-
order  in  the  general  population  and  contributes  not  only
to  a  major  deterioration  in  quality  of  life  but  also  to  an
increase  in  cardiovascular  morbimortality  [1—5];  AF  is  a real
public  health  problem,  the  effect  of  which  is  increasing
with  the  ageing  of  the  population.  AF  is  present  in  1—2%
of  the  general  population  and  affects  more  than  6  million
Europeans;  after  85  years  of  age,  the  prevalence  of  AF  can
be  as  high  as  20%.  The  principal  complication  of  AF  con-
cerns  thromboembolic  risk,  especially  stroke,  which  has  a
w
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mleak  prognosis  and  often  serious  neurological  sequelae.
hus,  AF  affects  the  prognosis  of  patients  directly,  with
 risk  of  death  multiplied  by  2,  and  an  increased  risk  of
troke  [6],  hospitalization  and  left  ventricular  (LV)  dysfunc-
ion.
Several  factors,  including  age,  arterial  hypertension,
eart  failure,  valvulopathy,  thyroid  disease  and  chronic
bstructive  pulmonary  disease,  promote  the  development
nd  persistence  of  AF.  In  addition,  myocardial  ischaemia,
hether  acute  or  chronic,  has  been  identiﬁed  as  one  of  the
rincipal  factors  in  the  onset  of  AF  and  its  persistence  in  the
edium-  and  long-term  [3—5,7,8].
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trial ﬁbrillation and myocardial infarction
yocardial  infarction  (MI)  is  one  of  the  major  physiopatho-
ogical  situations  that  promote  the  onset  of  AF.
pidemiology
he  incidence  of  AF  in  the  setting  of  MI  has  hardly  changed
ver  the  past  20  years.  Following  the  arrival  of  thromboly-
is  for  the  management  of  MI  in  the  acute  phase,  the  1997
USTO-I  study,  which  included  40,981  patients,  found  an
ncidence  of  7.9%  [26],  while  the  2005  OPTIMAAL  study  [9],
n  5477  patients,  reported  a  similar  incidence  of  7.2%.  Our
eam,  which  conducted  a  study  on  AF  after  non—ST-segment
levation  Min  (STEMI),  found  an  incidence  of  7.6%  [8].  In  a
ecent  study  that  evaluated  the  prognostic  effect  of  AF  after
TEMI  treated  with  primary  angioplasty,  the  reported  inci-
ence  was  6.4%  [10].  The  factors  affecting  the  onset  of  AF
n  the  acute  phase  of  MI  are  now  well  known;  those  found
ost  frequently  are  indicators  of  left  ventricular  (LV)  dys-
unction,  notably  Killip  class  IV  on  admission  and  increased
eart  rate  on  admission,  particularly  when  it  is  above  100
eats  per  minute.
Age  is  a  major  risk  factor,  and  is  very  frequently  associ-
ted  with  the  onset  of  AF  [11—13].  Other  variables,  including
 personal  history  of  AF,  certain  cardiovascular  risk  factors
uch  as  hypertension  or  type  2  diabetes,  as  well  as  LV  hyper-
rophy  have  been  identiﬁed  in  the  different  studies  [5].  In
ontrast,  MI  location,  type  of  reperfusion,  and  the  presence
f  ST-segment  elevation  do  not  appear  to  be  predictors  of
he  onset  of  AF  [14—16].  Although  the  overall  incidence  has
emained  stable  over  time,  it  varies  considerably  from  one
tudy  to  another,  ranging  from  2.3%  to  21%,  because  it  is
trongly  dependent  on  the  screening  method  used  and  the
uration  of  screening  [5].
The  diagnosis  of  AF  depends  on  the  discovery  of  rhythm
nomalies  meeting  the  deﬁnition  of  AF  according  to  Euro-
ean  recommendations  [17]:  strictly  irregular  RR  intervals
n  the  surface  electrocardiogram  (ECG);  absence  of  identi-
able  P  waves,  with  an  unidentiﬁable  isoelectric  line;  atrial
hythm  >  300  beats  per  minute  or  an  interval  between  two
trial  activations  <  200  ms.  The  diagnosis  of  AF  can  be  made
n  a  12-lead  surface  ECG  without  taking  the  duration  into
ccount,  or  on  an  ECG  readout  of  at  least  30  seconds  [17].
The  complications  associated  with  the  onset  of  AF
o  not  vary  according  to  the  type  of  episode.  Indeed,
hether  the  AF  is  paroxysmal,  persistent  or  permanent,  or
ymptomatic  or  silent,  it  can  be  complicated  by  serious  or
ife-threatening  thromboembolic  events.  Two  studies  have
hown  that  episodes  of  AF,  even  silent  or  infraclinical  AF,
re  associated  with  a  signiﬁcantly  increased  risk  of  stroke
r  other  thromboembolic  complications,  which  means  that
ystematic  screening  for  AF  is  essential  in  any  patients  with
schaemic  stroke  [18—21].  In  a  study  that  compared  dif-
erent  screening  methods  (noninvasive  [3-  or  7-day  Holter,
CG  monitor,  surface  ECG,  etc.],  invasive  [implantable  loop
ecorder]  or  even  intracardiac  recording  methods  [pace-
aker]),  the  authors  pointed  out  that  the  detection  of  AF,
hether  symptomatic  or  silent,  improved  with  the  duration
f  monitoring.  Although  there  was  no  clear  difference
etween  the  screening  methods,  they  noted  that  screening
g
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y  7-day  Holter  was  slightly  superior,  in  that  it  provided
ontinuous  screening  and  was  relatively  easy  to  use.
Nonetheless,  despite  meticulous  screening,  there  are  still
o  recognized  thresholds  for  AF  duration  or  the  frequency  at
hich  the  thromboembolic  risk  becomes  signiﬁcant.  Recom-
endations  for  the  use  of  anticoagulants  in  the  therapeutic
anagement  of  AF,  however,  only  take  into  account  embolic
isk  factors  (CHA2DS2-VASc  score)  and  not  AF  duration  or
requency  [21].
Today,  in  routine  clinical  practice  for  the  management  of
atients  in  the  acute  phase  of  MI,  continuous  ECG  monitor-
ng  (CEM)  is  set  up  for  the  ﬁrst  48  to  72  hours  of  their  stay
n  the  cardiac  intensive  care  unit.  The  diagnosis  of  AF  with
 CEM  apparatus  is  automatic;  it  is  based  on  the  application
f  algorithms  incorporated  in  the  software  of  the  apparatus,
hich  is  able  to  detection  a  rhythm  compatible  with  AF  in
nly  15  cardiac  cycles.  The  episode  is  considered  signiﬁcant
hen  it  lasts  for  at  least  30  seconds.  This  screening  system
akes  it  possible  to  prolong  the  screening  and  determine
he  precise  incidence  of  AF  after  MI.  In  addition,  automatic
etection  also  identiﬁes  infraclinical  episodes.  Recent  stud-
es  have  suggested  that  this  type  of  AF  is  frequent  after
troke  and  its  consequences  are  far  from  innocuous.
Systematic  screening  for  AF  after  MI  therefore  appears
o  be  a  key  element  in  the  management  of  patients.  In
ecent  studies,  our  team  showed  that  systematic  CEM  could
mprove  the  efﬁcacy  of  screening  for  episodes  of  AF  after
I  [22].  Indeed,  this  automated  screening  method  revealed
n  incidence  of  AF  of  21%,  among  which  three  of  four  were
pisodes  of  silent  AF,  thus  identiﬁed  by  the  CEM  only.
rincipal mechanisms and consequences
he  onset  of  AF  in  the  acute  phase  of  MI  is  a  major  event
hat  can  jeopardize  the  prognosis  of  patients  in  the  short-,
edium-  and  long-term;  it  is  a  powerful  predictor  of  a  poor
rognosis  after  MI  [5,20,23—27].  In  2005,  our  team  showed
hat  the  onset  of  AF  was  a  predictor  of  poor  prognosis  in
atients  with  non-STEMI  [8]. This  effect  on  prognosis  was
lso  reported  in  studies  on  STEMI  [28,29].  This  association
as  found  whatever  the  type  of  reperfusion  in  the  acute
hase.  Indeed,  recent  studies  reported  the  harmful  effect
f  AF  onset  in  the  acute  phase  of  MI  on  mortality,  even  in
atients  treated  with  angioplasty  [11,30,31].  The  suspected
echanism  underlying  this  excess  mortality  is  the  drop  in
oronary  ﬂow  linked  to  the  acceleration  and  arrhythmic
ature  of  the  LV  contractions,  which  reduce  the  LV  ejection
raction  (LVEF).  The  reduced  LVEF  could  explain  the  frequent
pisodes  of  heart  failure  following  the  onset  of  AF,  found
n  association  with  increased  LV  telediastolic  pressure  and
ncreased  left  atrial  (LA)  volume  [13]. Moreover,  by  exacer-
ating  LV  ischaemia,  AF  is  associated  with  an  increased  risk
f  severe  ventricular  rhythm  disorders  [29,30,32].
The  acute  phase  of  MI  corresponds  to  a  period  of  myocar-
ial  and  systemic  inﬂammation  associated  with  elevated
lasma  markers  [10,33,34].  This  inﬂammatory  process  acti-
ates  cellular  growth  factors  and  tissue  repair  mechanisms,
eading  to  atrial  ﬁbrosis  and  remodelling,  which  are  likely  to
enerate  the  anatomical  substrate  favourable  for  the  sub-
equent  onset  of  AF  and  its  persistence  over  time  [17].  The
ltrasound  LA  variables,  particularly  LA  volume,  indirectly
eﬂect  this  remodelling.  The  follow-up  of  patients  after  MI
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shows  that  those  who  develop  new  onset  AF,  those  whose
paroxysmal  AF  is  reactivated,  or  even  those  who  present
with  permanent  AF  on  admission  have  a  higher  inhospital
and  long-term  mortality  rate  than  patients  without  AF  after
MI  [5].  However,  certain  studies  suggest  that  this  mortality
rate  varies  according  to  the  type  of  AF.
Indeed,  in  the  OPTIMAAL  trial,  the  inhospital  mortality
rate  in  patients  who  developed  new  onset  AF  in  the  acute
phase  of  MI  was  higher  than  that  in  patients  without  AF.  This
difference,  however,  was  not  found  between  patients  with
AF  on  admission  and  those  without  AF  [9]. Moreover,  the
study  by  Jabre  et  al.  provided  additional  details,  by  show-
ing  that  the  prognosis  in  patients  who  developed  de  novo  AF
depended  on  when  the  AF  occurred.  Indeed,  the  mortality
rate  in  patients  who  developed  AF  beyond  30  days  after  MI
was  twice  that  in  patients  without  AF  after  MI  and  greater
than  that  in  patients  who  developed  AF  between  the  second
and  thirtieth  day  after  MI  [20].  However,  the  early  post-
MI  period,  notably  the  ﬁrst  48  hours,  was  the  peak  period
for  the  onset  of  episodes  of  AF,  and  included  30%  of  such
episodes.  As  shown  above,  the  time  to  onset  of  AF  after
MI  affects  the  prognosis.  Another  major  element  leading  to
excess  mortality  is  impaired  LVEF,  according  to  data  from
the  VALIANT  study  [24].
The  principal  causes  of  AF-associated  death  after  MI  are
linked  to  heart  failure  [9].  Moreover,  the  excess  risk  of  death
in  these  heart  failure  patients  has  also  been  associated  with
the  onset  of  sudden  death,  with  an  odds  ratio  of  1.33  (95%
conﬁdence  interval  1.19—1.49;  P  <  0.001)  [35].
Finally,  the  principal  complication  of  AF,  namely  stroke,
has  also  been  studied.  Three  important  studies  showed  a
higher  incidence  of  stroke  after  MI  in  patients  who  experi-
enced  AF  in  the  acute  phase.  The  analysis  of  data  from  the
GUSTO-I  trial  showed  a  stroke  incidence  of  3.1%  in  patients
who  presented  with  AF  in  the  acute  phase,  compared  with
1.3%  in  patients  in  sinus  rhythm.  In  this  study,  involving  more
than  40,000  patients,  most  of  the  strokes  were  ischaemic
[36].
The  onset  of  AF,  when  it  occurs  during  the  acute  phase
of  MI,  is  a  serious  event  because  it  increases  the  risk  of
stroke  in  the  medium-  and  long-term,  and  is  responsible  for
the  increased  mortality  most  often  linked  to  heart  failure
and  sudden  death.  Although  numerous  studies  have  investi-
gated  the  conditions  surrounding  the  onset  of  AF,  the  precise
physiopathological  mechanisms  responsible  for  the  onset  of
AF  in  the  acute  phase  of  MI  are  still  unclear;  they  notably
involve  atrial  ischaemia,  increased  LV  telediastolic  pres-
sure  and  its  effect  on  the  left  atrium  (LA),  neurohormonal
phenomena  and  their  link  with  atrial  hyperexcitability  and,
ﬁnally,  oxidative  stress.
Implication of oxidative stress in myocardial
infarction
Oxidative  stress  corresponds  to  an  imbalance  between
the  pro-oxidant  and  antioxidant  systems.  During  an
ischaemia/reperfusion  sequence,  the  oxidative  balance  tilts
in  favour  of  the  production  of  free  radical  species,  such  as
superoxide  anion  [37].  An  increase  in  oxidative  stress,  which
is  a  target  of  choice  for  future  therapies,  could  be  an  impor-
tant  mediator  of  atrial  remodelling  [38].  Indeed,  studies
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n  animal  models  have  suggested  that  the  oxidative  stress
athway  is  one  of  the  pathways  via  which  inﬂammation
ould  trigger  AF.  In  a dog  model  of  pacemaker-induced  AF,
 fall  in  tissue  antioxidant  defences  (ascorbic  acid)  and  an
ncrease  in  markers  of  nitro-oxidative  stress  were  observed
39]. Moreover,  in  a  recent  study  in  pigs  subjected  to  rapid
trial  stimulation  for  a  week  to  trigger  the  onset  of  AF,  the
oncentration  of  superoxide  anion  production  in  atrial  tissue
n  the  AF  pigs  was  three  times  greater  than  that  in  control
igs  without  AF  [40].  In  addition,  the  analysis  of  atrial  tissue
rom  patients  after  a Maze  operation  showed  oxidative-type
lterations  in  the  myoﬁbrils  in  the  appendages  (especially
he  LA  appendage)  in  these  patients  with  chronic  AF.  This
amage  was  attributed  to  the  release  of  peroxynitrites  and
ydroxyl  radicals.  These  free  radical  species  lead  to  the
ormation  of  carbonylated  proteins  and  nitrotyrosine,  sug-
esting,  in  humans,  that  an  oxidative  process  takes  place
n  the  atrial  myocardium  of  patients  with  chronic  AF.  This
tudy  indicates  that  oxidative  stress  has  a  major  effect  on
he  electrophysiological  and  mechanical  properties  of  atrial
yocytes,  resulting  in  remodelling  that  favours  the  devel-
pment  and  persistence  of  AF.
Age  is  also  a  major  risk  factor  of  the  development  of  AF.
ge  correlates  with  the  level  of  oxidative  stress  [41],  thus
einforcing  the  hypothesis  of  a  link  between  oxidative  stress
nd  AF.
Another  pathway  probably  implicated  in  the  onset  of  AF
s  endothelial  dysfunction.  Indeed,  Kim  et  al.  showed  that
itric  oxide  synthase  decoupling  was  implicated  in  the  pro-
uction  of  superoxide  anion  by  myocardial  tissue  of  the  atria
f  patients  with  AF  [42]. This  excess  of  free  radical  species
auses  damage  to  the  myoﬁbrils  responsible  for  structural
emodelling,  leading  to  the  development  of  AF  and  the  sub-
equent  risk  of  thrombus  formation  [43,44].
Among  the  factors  likely  to  modulate  the  bioavailability
f  nitric  oxide,  certain  derivatives  of  L-arginine,  includ-
ng  asymmetric  NG,NG-dimethyl  L-arginine  (ADMA)  and  its
tereoisomer  symmetric  NG,N’G-dimethyl  L-arginine  (SDMA),
ave  recently  been  proposed  as  new  biomarkers  in  cardio-
ascular  diseases  [45,46].  In  1998,  Usui  et  al.  reported  high
irculating  concentrations  of  ADMA  in  heart  failure  patients
ith  permanent  AF  [47].  Cengel  et  al.  also  showed  that  ADMA
oncentrations  in  patients  who  developed  de  novo  AF  were
igher  than  those  in  patients  with  chronic  AF  [48]. Goette
t  al.  very  recently  showed  a  fall  in  ADMA  concentrations
fter  cardioversion  [49].  This  modiﬁcation  in  circulating  con-
entrations  of  ADMA  could  be  a  consequence  of  the  AF,  but
lso  a  cause  of  the  onset  of  AF.  Indeed,  certain  studies
ave  shown  that  high  ADMA  concentrations  were  associated
ith  a more  frequent  recurrence  of  AF  after  cardioversion
r  a  radiofrequency  ablation  procedure  [50,51].  In  patients
ith  ischaemic  heart  disease  and  AF,  a  high  concentration
f  ADMA  was  shown  to  be  a risk  factor  for  cardiovascular
dverse  events,  including  ischaemic  stroke  or  cardiovascular
eath.  A  high  concentration  of  ADMA  (>  0.55  mol/L)  is  a  risk
actor  that  is  independent  of  LA  size  and  the  CHA2DS2-VASc
core  [52].
It  therefore  appears  that  the  methylated  derivatives  of
-arginine  could  potentially  be  implicated  in  the  onset  of
F  and  its  effect  on  the  prognosis  of  patients.  In  a  recent
tudy,  we  were  able  to  show  that  the  plasma  concentration
f  ADMA  was  an  independent  predictive  factor  of  the  onset
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f  AF  in  the  acute  phase  of  MI.  This  study  was  the  ﬁrst  to
uggest  that  ADMA  was  a  possible  cause  of  AF  onset,  and  not
ust  a  consequence  of  a  local  increase  in  oxidative  stress
inked  to  the  loss  of  atrial  systole  and  LA  stretching  [53].
ltrasound left atrial size variables: value in
trial ﬁbrillation
A  enlargement  has  long  been  known  as  a  risk  factor  for
he  onset  and  persistence  of  AF  [22,27].  Ultrasound  evalua-
ion  of  LA  variables  quickly  became  the  reference  method  to
etermine  LA  enlargement  in  this  context.  Complementary
tudies  provided  evidence  of  the  direct  prognostic  effect
f  this  variable  [54],  by  identifying  LA  enlargement  as  an
ndependent  predictor  of  a  poor  prognosis,  associated  with
ncreases  in  all-cause  mortality  after  MI,  in  the  risk  of
troke  and  in  rehospitalization  for  cardiac  decompensation
n  patients  with  heart  failure  [54—57].  To  explain  this  asso-
iation,  it  was  suggested  that  LA  enlargement  was  a  marker
f  the  severity  and  chronicity  of  high  LA  ﬁlling  pressure  and
hus  diastolic  dysfunction  of  the  left  ventricle  (LV)  [58,59].
Different  threshold  values  for  LA  enlargement,  assessed
ccording  to  diameter,  area  and  volume,  have  been  pro-
osed  by  the  European  Association  of  Cardiovascular  Imaging
nd  the  American  Society  of  Echocardiography  [60].  LA  vol-
me,  especially  when  its  value  is  indexed  to  body  area,  is
 particularly  robust  variable  for  determining  LA  enlarge-
ent,  and  was  validated  by  comparison  with  measurements
y  computed  tomography  or  cardiac  magnetic  resonance
maging.  LA  volume  appears  to  correlate  better  with  car-
iovascular  diseases,  probably  because  it  provides  a  better
valuation  of  the  sometimes  asymmetrical  remodelling  of
he  left  atrium  [12].  These  data  were  conﬁrmed  by  a  study
n  patients  in  sinus  rhythm,  which  compared  the  value  of
A  size  evaluated  using  either  the  diameter,  area  or  volume
s  a  predictor  of  a  poor  prognosis  [61].  Our  studies  showed
hat  the  area  of  the  LA  indexed  to  body  area  could  also  be
n  excellent  tool  in  routine  practice  to  evaluate  the  risk  of
F  onset  in  patients  in  the  acute  phase  of  MI.  In  multivari-
ble  analysis,  this  variable  appeared  to  be  an  independent
redictor  of  AF,  and  this  beyond  the  indexed  volume  [22,62].
hese  results  can  probably  be  explained  by  the  accuracy  of
ltrasound  measurements.  The  area  in  apical  four-chamber
nd  two-chamber  views  is  measured  directly  by  the  oper-
tor,  while  the  volume  is  calculated  from  the  areas  and
ongitudinal  diameters  obtained  in  the  apical  four-chamber
nd  two-chamber  views.  The  longitudinal  diameters,  how-
ver,  may  vary  considerably  depending  on  the  view,  the
oment  in  the  cardiac  cycle  and  even  the  quality  of  the
mage  obtained.
In  our  study,  LA  enlargement  was  an  independent  risk
actor  for  inhospital  death  at  1  year  after  the  acute  phase.
his  major  result  underlines  the  central  role  of  the  LA  in  the
nset  of  AF  and  in  its  prognostic  consequences  in  the  acute
hase  of  MI  [62].
In  light  of  these  data,  it  seemed  interesting  to  evalu-
te  LA  function  more  precisely  using  more  robust  tools,
uch  as  speckle  tracking  of  the  LA.  Indeed,  this  variable,
hich  is  easy  to  assess  using  current  ultrasound  techniques,
as  shown  its  predictive  value  in  the  maintenance  of  sinus
hythm  after  cardioversion  using  external  electric  shock
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63]. Moreover,  in  patients  after  non-STEMI,  the  impair-
ent  of  LA  function  evaluated  by  speckle  tracking  was
igniﬁcantly  greater  than  that  caused  by  simple  enlarge-
ent  evaluated  by  the  usual  variables.  In  addition,  this
mpaired  deformation  of  the  LA  was  signiﬁcantly  associated
ith  impaired  LV  function  [64], suggesting  that  it  could  help
s  to  understand  the  mechanisms  leading  to  the  onset  of  AF
fter  MI.
ilent atrial ﬁbrillation in the acute phase
f myocardial infarction
F  is  a  frequent  event  in  the  ﬁrst  hours  after  MI,  as  5%  of
atients  present  symptomatic  AF.  We  showed  for  the  ﬁrst
ime  that  silent  AF,  with  an  incidence  of  16%  in  the  acute
hase  of  MI,  is  three  times  more  frequent  than  symptomatic
F.
As  in  symptomatic  AF,  old  age  and  a history  of  AF  are
ssociated  with  a  high-risk  of  silent  AF.  Moreover,  the  anal-
sis  of  LA  size  variables  showed  for  the  ﬁrst  time  that  LA
nlargement  is  an  independent  predictor  of  the  onset  of
oth  symptomatic  and  silent  AF  in  the  acute  phase  of  MI.
Whatever  its  form,  AF  has  a  major  negative  effect  on
he  prognosis  of  patients.  In  our  studies,  symptomatic  AF
as  associated  with  an  inhospital  mortality  rate  of  17.8%,
o  which  can  be  added  a mortality  rate  at  1  year  of  18.8%
62]. Surprisingly,  silent  AF  also  has  a  negative  effect  on
rognosis,  as  it  is  associated  with  an  inhospital  mortality
ate  of  10.4%,  which  remains  high  at  5.7%  at  1  year  [62].
oreover,  both  forms  of  AF  are  independent  predictors  of
ortality  beyond  traditional  risk  factors.  The  frequency  and
eriousness  of  silent  AF  in  the  short-  and  long-term,  which
ere  rarely  studied  until  recently,  raises  the  question  of
ystematically  screening  for  AF  in  the  acute  phase  of  MI,
nd  thus,  if  found,  its  speciﬁc  management.  The  compara-
ive  analysis  of  the  prognosis  in  patients  with  symptomatic
nd  silent  AF  showed  that  during  the  inhospital  period,
atients  with  symptomatic  AF  had  more  episodes  of  heart
ailure.  In  contrast,  during  the  ﬁrst  year  after  MI,  the  lev-
ls  of  hospitalization  for  heart  failure  were  similar  (6.3%  vs.
.6%).  In  our  studies,  however,  patients  with  symptomatic
F  had  a  signiﬁcantly  lower  LVEF  at  admission  for  MI  (40%
s.  50%  for  symptomatic  versus  silent  AF,  respectively)  [62].
o  explain  these  apparently  contradictory  ﬁndings,  Holter
nalysis  1  month  after  the  event  could  make  it  possible  to
etermine  the  risk  of  developing  AF  (paroxysmal  or  persis-
ent).  There  is  also  the  question  of  verifying  the  hypothesis
ccording  to  which  LVEF  in  patients  who  present  silent  AF
eteriorates  after  they  have  left  hospital.  The  role  played
y  heart  rhythm  disorders  in  the  impairment  of  LV  function
hus  needs  to  be  determined.
As  we  have  already  pointed  out,  given  the  negative  effect
f  silent  AF  on  prognosis,  which  was  brought  to  light  only
ecently,  the  question  of  managing  silent  AF  arises.  The  ini-
iation  of  anticoagulation  therapy  in  these  patients,  most
f  whom  are  already  taking  dual  antiplatelet  therapy,  must
e  discussed.  Indeed,  we  showed  that  patients  who  present
ith  AF  are  most  often  treated  with  vitamin  K  antagonists
fter  discharge  from  hospital  (27%  of  patients  with  silent
F  and  50%  of  patients  with  symptomatic  AF)  [62].  Although
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we  did  not  evaluate  the  haemorrhagic  risk,  these  data  sug-
gest  that  haemorrhagic  events  may  have  been  implicated  in
the  excess  mortality  of  such  patients.  Our  studies  showed
that  although  all-cause  mortality  was  higher  in  the  groups
with  AF,  most  deaths  were  related  to  cardiovascular  dis-
ease.  However,  levels  of  recurrent  infarction  were  similar  in
the  three  groups,  and  the  statistical  power  was  too  low  to
analyse  mortality  related  to  stroke.  In  contrast,  the  rhythm
analysis  data  provided  by  the  CEM  showed  that  the  pro-
portion  of  symptomatic  AF  patients  with  severe  ventricular
rhythm  disorders  (ventricular  tachycardia  and  ﬁbrillation)
was  greater  than  that  in  patients  without  AF  (24.4%  vs.
4.3%),  which  could  explain  the  excess  mortality.
The  study  of  the  treatments  showed  that,  in  the  acute
phase,  when  the  risk  of  rhythm  disorder  is  maximal,  these
patients  were  of  course  more  likely  to  be  treated  with  amio-
darone  and  digoxin,  but  paradoxically  were  less  likely  to  be
treated  with  beta-blockers.  This  difference  regarding  beta-
blockers  was  not  found  at  discharge;  it  therefore  does  not
explain  the  excess  risk  of  cardiovascular  death  at  1  year  [62].
Nonetheless,  we  showed  that  angiotensin-converting
enzyme  inhibitors  were  still  underused  in  patients  with
AF  [62].  It  would  appear  interesting  in  the  context  of
prospective  studies  to  analyse  the  effect  of  atrial  and
ventricular  remodelling  on  the  onset  of  severe  ventricu-
lar  rhythm  disorders,  and  the  effect  of  treatments  with
angiotensin-converting  enzyme  inhibitors  or  angiotensin  II
receptor  blockers  on  these  AF-related  disorders.  A  subgroup
analysis  according  to  treatment  with  beta-blockers  at  the
acute  phase  would  make  it  possible  to  determine  whether
patients  not  treated  with  beta-blockers  had  an  excess  risk
of  death.  Deﬁning  an  appropriate  management  strategy  that
takes  into  account  the  speciﬁc  risks  of  this  high-risk  popu-
lation  appears  to  be  an  important  clinical  challenge.  This
is  particularly  true  when  data  relative  to  the  LVEF  are  ana-
lysed  in  detail:  impaired  LVEF  is  a  major  determinant  of  the
risk  of  developing  AF  [22,62].  The  link  between  AF  and  LVEF
could  explain  the  worse  prognosis  in  these  patients.  In  our
study,  however,  we  showed  that  even  in  the  subgroup  of
patients  with  a  preserved  LVEF  (LVEF  >  40%),  silent  AF  was  an
independent  predictor  of  death  [62].  Therefore,  this  speciﬁc
population  of  patients  with  AF  are  probably  underidentiﬁed
and  undertreated,  notably  because  the  exact  reasons  for
their  poor  prognosis  have  not  yet  been  determined.
Conclusion
AF  in  the  acute  phase  of  MI  is  a  frequent  and  serious
event  with  a  major  effect  on  the  prognosis  of  patients.
In  light  of  recent  studies,  it  appears  that  no  forms  of  AF
should  be  ignored,  and  we  underline  in  particular  the  impor-
tance  of  screening  for  silent  AF,  which  appears  to  be  the
most  frequent  form  in  the  acute  phase  of  MI.  The  use
of  CEM  is  a  simple,  effective  and  inexpensive  solution  to
improve  screening  for  AF  immediately,  although  comple-
mentary  studies  are  still  necessary  to  validate  this  strategy.
Finally,  complementary  studies  also  need  to  be  conducted  to
understand  the  pathophysiological  mechanisms,  especially
the  effect  of  oxidative  stress  and  endothelial  dysfunction,
which  seem  to  play  a  major  role  in  triggering  this  rhythm
disorder.
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